We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


OGT Releases New Whitepaper for Aiding Biomarker Discovery

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OGT Releases New Whitepaper for Aiding Biomarker Discovery"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Oxford Gene Technology (OGT) has released a new whitepaper entitled ‘Autoantibody biomarker panels for improved disease diagnosis’. The free-to-download document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development.

Autoantibodies are produced by the host immune system and as such are often detectable during the early stages of disease onset. In addition, they are stable, abundant, highly specific and easily purified from serum, making them ideal candidates for use in disease detection. The issues surrounding the use of autoantibodies as biomarkers are discussed in detail in the whitepaper, including their relative advantages, selection of the most appropriate discovery technology and choosing between strategies for in-house or outsourced discovery.